Sepracor initiated with "hold" -update-

05/08/06 - A.G. Edwards & Sons

NEW YORK, May 8 (newratings.com) - Analyst Aaron S Reames of AG Edwards initiates coverage of Sepracor Inc (SEPR) with a "hold" rating. The fair value is set to $44.

In a research note published on May 4, the analyst mentions that the company has three approved products, including Lucenta and Xopenex. Sepracor is expected to become profitable this year without requiring additional financing, the analyst says. On the other hand, the company is facing stiff competition across all sectors and may require increasing marketing expenditures to effectively compete, since the market share growth for Xopenex and Lunesta is likely to slow in 2006, AG Edwards adds.